AI, Biotechs and Gamestop moving this morning

What you need to know                                                                                                                                                                                                                                                                                                                                                                                                                 May 28, 2024 | [Read Online]( AI, Biotechs and Gamestop moving this morning *sponsored by Shore Thing Media Good morning, 360! Join Jeff Bishop for a [special session TODAY@ 2pm EST]( to hear the latest about how he's been running down trades with triple-digit potential with his custom Gamma Trigger System. Be the best prepared trader on the Street! FOCUS LIST🔎 POAI - Up over 50% in the pre-market after-its AI tech helps achieve positive results in Ovarian Cancer Study with UPMC Magee-Womens Hospital INSM - Up over 130% in pre after Phase 3 success of Brensocatib in patients with Bronchiectasis GME - Up over 20% in pre after announcing it had raised over $933 million from the sale of 45 million shares. *sponsored by Shore Thing Media [Missed NVIDIA? Newly Listed Company Aims to Be the Future of AI Investment]( With a stake in the world’s fastest AI servers, this company is democratizing the AI landscape and generating millions in revenue in the process. “The Second AI Wave Is Forming,” according to Money & Markets. [>> Don’t miss this one!]( 🏄 *Sponsored content/paid advertisement. This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. HOTLIST🔥 POAI - Up over 50% in the pre-market after-its AI tech helps achieve positive results in Ovarian Cancer Study with UPMC Magee-Womens Hospital Predictive Oncology Inc. (POAI) is a knowledge and science-driven company that applies artificial intelligence (AI) to support the discovery and development of optimal cancer therapies. In the pre-market this morning, the [company announced]( positive results from ovarian cancer study with UPMC Magee-Womens Hospital to be presented at the 2024 American Society of Clinical Oncology (ASCO) annual meeting. The study successfully demonstrated Predictive’s ability to build AI multi-omic machine learning models to predict survival outcomes among ovarian cancer patients better than clinical data alone The stock traded up over 50% in the pre-market in reaction to the news. The $2.30 area has acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $2.60 and then the pre-market high at $2.80. Beyond that, $3, $3.50, $3.75 and $4 come into play. Below $2.30, targets to the downside are $2.06, $1.80 and then a gap fill at $1.57. INSM - Up over 130% in pre after Phase 3 success of Brensocatib in patients with Bronchiectasis Insmed Incorporated (INSM) is a biopharmaceutical company that develops and commercializes therapies for patients with serious and rare diseases in the United States and internationally. In the pre-market the [company announced]( positive topline results from landmark Aspen study of Brensocatib in patients with Bronchiectasis. The ASPEN study was a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of Brensocatib in patients with non-cystic fibrosis bronchiectasis. The study met its primary endpoint, with both dosage strengths of Brensocatib demonstrating statistically significant reductions in the annualized rate of pulmonary exacerbations (PEs) versus placebo. The study also met several of its prespecified secondary endpoints with statistical significance. Treatment with Brensocatib also achieves statistical significance on multiple secondary endpoints for both dosage strengths versus placebo. Based on these results, Insmed plans to file a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for brensocatib in patients with bronchiectasis in the fourth quarter of 2024. The stock traded up over 130% in the pre-market in reaction to the Phase 3 results. The $50.50 area has acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $53.79, $60 and then the pre-market high at $64. Beyond that is all-time highs and blue sky. Below $50.50, targets to the downside are $48, $46.28, $45, $44, $40 and then $36. Grab This Discount Before It’s Gone… [Includes Bullseye Unlimited!]( Expires in JUST… Don’t forget Jeff’s [LIVE session TODAY@ 2pm EST]( to hear MORE! GME - Up over 20% in pre after announcing it had raised over $933 million from the sale of 45 million shares. GameStop Corp. (GME) is a specialty retailer that provides games and entertainment products through its stores and ecommerce platforms in the United States and internationally. In the after-hours Friday, [GME announced]( that it had raised over $933 million from the sale of 45 million shares. The sale of stock had put pressure on the MEME name after an explosive move a couple of weeks ago and with the sale completed, GME is up over 20% in the pre-market this morning. The first target for bulls is the pre-market high at $24.30. Above it, targets to the upside are $25, $27.50, $28 and $30. Below $24.30, targets to the downside are $22.50, $21.50, $20 and then a gap fill at $19. MARKET NEWS 📰 👊 Make sure you are getting my mobile text alerts –  text “RAGE” to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the “1” at the front!). Don’t miss out! Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull *Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.” Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received five thousand dollars (cash) from Shore Thing Media for advertising ALSET CAPITAL INC for a four-day marketing program starting on May 28 and ending on May 31 of 2024. This amount was paid by someone else not connected to ALSET CAPITAL INC. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case. Now, diving right into ALSET CAPITAL INC might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r. Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now. Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization. So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture. [tw]( Update your email preferences or unsubscribe [here]( © 2024 360 WallStreet 62 Calef Hwy. #233 lee, NH 03861, United States of America